drugset
drugset / Trial / NCT05919069

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

NCT05919069 ↗

Phase 1 Completed 35 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelOther

Summary

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Timeline

Start
2023-06-16
Primary completion
2024-09-16
Completion
2024-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2693 Antisense oligonucleotide — Subcutaneous

Indications

No indication recorded.